Price movement over the last 24 hours
Agilent Technologies Inc vs Capri Holdings Ltd — how do they compare? Agilent Technologies Inc trades at $128.41 (market cap $37.04B), while Capri Holdings Ltd trades at $17.79 (market cap $2.23B). The key difference: Agilent Technologies Inc is far larger — about 16.6× Capri Holdings Ltd's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| A | CPRI | |
|---|---|---|
Market Cap | $37.04B | $2.23B |
Sector | Health | Consumer Staples |
52-Week High | $157.20 | $27.66 |
52-Week Low | $110.24 | $16.79 |
Enterprise Value | $38.59B | $3.51B |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
CPRI trades at $19.41, up 2.37% today, amid mixed signals with bearish technical indicators but improving fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $0.22 versus $0.118, while revenue trends show stabilization after declines. The company's net income margin improved to 3.94% for 2026, though 2025 saw a significant loss. Analyst consensus is mixed with 44% buy ratings and a $23.43 price target, suggesting potential upside from current levels.
The outlook hinges on CPRI's turnaround execution, with risks including luxury demand volatility and high debt. Positive catalysts include projected FY2027 growth and cost management efforts. Investors should weigh the attractive P/S ratio of 0.65 against ongoing operational challenges and insider selling noted in recent filings.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →